Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?

Table 2

Overall survival and cancer-specific survival by therapeutic modality, adapted from Culp et al. (2014) [13].

Therapeutic modality	5-year OS rate (%)	5-year CSS rate (%)
RP	67,4	75,8
BT	52,6	61,3
NLT	22,5	48,7

OS: overall survival; CSS: cancer-specific survival; RP: radical prostatectomy; BT: brachytherapy; NLT: no local treatment.